Skip to main content
NeopharmCO.,LTD. logo

NeopharmCO.,LTD. — Investor Relations & Filings

Ticker · 092730 ISIN · KR7092730001 KO Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2024-02-02 Earnings Release
Country KR South Korea
Listing KO 092730

About NeopharmCO.,LTD.

https://neopharm.co.kr

Neopharm is a science-based company specializing in the development, manufacturing, and sale of dermatological skincare and cosmetic products. A pioneer in skin barrier research, the company focuses on restoring skin homeostasis. Its core innovation is the proprietary Multi-Lamellar Emulsion (MLE) technology, which mimics the natural lipid structure of the skin to repair and strengthen its protective functions. The company's primary product lines, including the flagship brand Atopalm, are specifically formulated for sensitive, dry, and compromised skin. These non-steroid solutions are grounded in dermatological science to address various skin concerns.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (NeoPharm) announcing a significant change in financial results (revenue/profit structure). This type of disclosure is a standard requirement for listed companies in Korea to report preliminary earnings results before the final audited annual report is published. It provides key financial highlights and reasons for the change, fitting the definition of an Earnings Release (ER). FY 2023
2024-02-02 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Preliminary Earnings Report' (영업(잠정)실적) for Neopharm, detailing quarterly financial performance (revenue, operating profit, net income) for the period ending 2023.12.31. It is a standard regulatory disclosure of financial results, which fits the definition of an Earnings Release (ER) as it provides key financial highlights before the full audit is completed. Q4 2023
2024-02-02 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Neopharm regarding the decision to pay a cash dividend. It specifies the dividend amount per share (750 KRW), the dividend yield, the record date (2023-12-31), and the board resolution date. This fits the definition of a 'Notice of Dividend Amount' (DIV) perfectly.
2024-02-02 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory notice from Neopharm regarding the setting of a record date for the purpose of determining shareholders eligible to vote at the 24th Annual General Meeting. It does not contain the full report or proxy materials themselves, but rather serves as a formal regulatory announcement of a corporate action (setting a record date). Given the nature of the announcement and the lack of a specific category for 'Record Date' notices, it falls under the general regulatory filing category.
2023-12-08 Korean
합병등종료보고서(자산양수도)
M&A Activity Classification · 100% confidence The document is a 'Report on the Completion of Merger, etc.' (합병등종료보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the finalization of a tangible asset acquisition (real estate and facilities) by Neopharm. While the title mentions 'merger', the content specifically describes an asset acquisition (자산양수도) and confirms the completion of payment. Since this is a formal regulatory filing regarding a corporate transaction (M&A/Asset acquisition) that has been completed, it falls under the M&A Activity category.
2023-11-30 Korean
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for NeoPharm, covering the period from January 1, 2023, to September 30, 2023. It contains detailed company information, business descriptions, and financial data structures typical of a formal quarterly filing submitted to the Financial Supervisory Service (FSS) and the Korea Exchange. This fits the definition of an Interim/Quarterly Report (IR). 9M 2023
2023-11-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.